175 related articles for article (PubMed ID: 11295470)
1. Genetic susceptibility to multiple sclerosis: detection of polymorphic nucleotides and an intron in the 3' untranslated region of the major histocompatibility complex class II transactivator gene.
Rasmussen HB; Kelly MA; Clausen J
Hum Immunol; 2001 Apr; 62(4):371-7. PubMed ID: 11295470
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus.
Koizumi K; Okamoto H; Iikuni N; Nakamura T; Kawamoto M; Momohara S; Ichikawa N; Furuya T; Kotake S; Taniguchi A; Yamanaka H; Kamatani N
Ann Rheum Dis; 2005 Jun; 64(6):947-50. PubMed ID: 15897313
[TBL] [Abstract][Full Text] [Related]
3. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
[TBL] [Abstract][Full Text] [Related]
4. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).
Patarroyo JC; Stuve O; Piskurich JF; Hauser SL; Oksenberg JR; Zamvil SS
Genes Immun; 2002 Feb; 3(1):34-7. PubMed ID: 11857059
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: identification of a novel regulatory region in the 5'-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes.
van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Nov; 169(9):5061-71. PubMed ID: 12391222
[TBL] [Abstract][Full Text] [Related]
7. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III.
Holling TM; van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Jan; 168(2):763-70. PubMed ID: 11777970
[TBL] [Abstract][Full Text] [Related]
8. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.
Holtz R; Choi JC; Petroff MG; Piskurich JF; Murphy SP
Biol Reprod; 2003 Sep; 69(3):915-24. PubMed ID: 12748124
[TBL] [Abstract][Full Text] [Related]
9. MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.
Naves R; Lennon AM; Barbieri G; Reyes L; Puga G; Salas L; Deffrennes V; Rosemblatt M; Fellous M; Charron D; Alcaïde-Loridan C; Bono MR
Int Immunol; 2002 May; 14(5):481-91. PubMed ID: 11978778
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a B-cell-specific promoter for the human class II transactivator.
Lennon AM; Ottone C; Rigaud G; Deaven LL; Longmire J; Fellous M; Bono R; Alcaïde-Loridan C
Immunogenetics; 1997; 45(4):266-73. PubMed ID: 9002447
[TBL] [Abstract][Full Text] [Related]
11. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
12. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
13. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.
Piskurich JF; Gilbert CA; Ashley BD; Zhao M; Chen H; Wu J; Bolick SC; Wright KL
Mol Immunol; 2006 Feb; 43(6):519-28. PubMed ID: 15950283
[TBL] [Abstract][Full Text] [Related]
14. K-562 cells lack MHC class II expression due to an alternatively spliced CIITA transcript with a truncated coding region.
Day NE; Ugai H; Yokoyama KK; Ichiki AT
Leuk Res; 2003 Nov; 27(11):1027-38. PubMed ID: 12859996
[TBL] [Abstract][Full Text] [Related]
15. DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells.
Murphy SP; Holtz R; Lewandowski N; Tomasi TB; Fuji H
J Immunol; 2002 Sep; 169(6):3085-93. PubMed ID: 12218125
[TBL] [Abstract][Full Text] [Related]
16. Both qualitative and quantitative genetic variation of MHC class II molecules may influence susceptibility to autoimmune diseases: the case of endemic pemphigus foliaceus.
Piovezan BZ; Petzl-Erler ML
Hum Immunol; 2013 Sep; 74(9):1134-40. PubMed ID: 23777927
[TBL] [Abstract][Full Text] [Related]
17. Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune diseases.
Yau AC; Piehl F; Olsson T; Holmdahl R
Immunology; 2017 Apr; 150(4):408-417. PubMed ID: 27861821
[TBL] [Abstract][Full Text] [Related]
18. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
19. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
[TBL] [Abstract][Full Text] [Related]
20. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene.
Peijnenburg A; Van den Berg R; Van Eggermond MJ; Sanal O; Vossen JM; Lennon AM; Alcaïde-Loridan C; Van den Elsen PJ
Immunogenetics; 2000 Jan; 51(1):42-9. PubMed ID: 10663561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
